2022
Effects of Music Therapy on Quality of Life in Adults with Sickle Cell Disease (MUSIQOLS): A Mixed Methods Feasibility Study [Erratum]
Rodgers-Melnick S, Lin L, Gam K, Souza de Santana Carvalho E, Jenerette C, Rowland D, Little J, Dusek J, Bakshi N, Krishnamurti L. Effects of Music Therapy on Quality of Life in Adults with Sickle Cell Disease (MUSIQOLS): A Mixed Methods Feasibility Study [Erratum]. Journal Of Pain Research 2022, 15: 1123-1124. PMID: 35469252, PMCID: PMC9034844, DOI: 10.2147/jpr.s370799.Peer-Reviewed Original ResearchEffects of Music Therapy on Quality of Life in Adults with Sickle Cell Disease (MUSIQOLS): A Mixed Methods Feasibility Study
Rodgers-Melnick S, Lin L, Gam K, de Santana Carvalho E, Jenerette C, Rowland D, Little J, Dusek J, Bakshi N, Krishnamurti L. Effects of Music Therapy on Quality of Life in Adults with Sickle Cell Disease (MUSIQOLS): A Mixed Methods Feasibility Study. Journal Of Pain Research 2022, 15: 71-91. PMID: 35046718, PMCID: PMC8760983, DOI: 10.2147/jpr.s337390.Peer-Reviewed Original ResearchSickle cell diseaseQuality of lifePreliminary efficacyMT participantsCell diseaseWaitlist controlMusic therapyPROMIS Pain InterferencePROMIS sleep disturbanceMixed methods feasibility studyMusic therapy protocolMethods feasibility studyMusic therapy interventionSelf-management skillsPain interferenceSleep disturbancesTherapy interventionWLC participantsTherapy protocolsDiary completionClinical researchTherapyAdultsEfficacyMixed methods intervention design
2021
Sustained Improvements in Patient-Reported Quality of Life up to 24 Months Post-Treatment with LentiGlobin for Sickle Cell Disease (bb1111) Gene Therapy
Walters M, Tisdale J, Mapara M, Krishnamurti L, Kwiatkowski J, Aygun B, Kasow K, Rifkin-Zenenberg S, Jaroscak J, Garbinsky D, Chirila C, Gallagher M, Zhang X, Ho P, Thompson A, Kanter J. Sustained Improvements in Patient-Reported Quality of Life up to 24 Months Post-Treatment with LentiGlobin for Sickle Cell Disease (bb1111) Gene Therapy. Blood 2021, 138: 7. DOI: 10.1182/blood-2021-146905.Peer-Reviewed Original ResearchPain intensity numeric rating scaleNumeric rating scaleVaso-occlusive eventsSickle cell diseasePatient-reported outcomesCurrent equity holderMonth 24Severe vaso-occlusive eventsBaseline scoresQuality of lifeBluebird BioPopulation normsException of anxietyComplete resolutionGroup CSmall sample size limits interpretationMean pain interference scoreSevere sickle cell diseaseUS general population normsAdvisory CommitteePatient-reported QOL outcomesMean pain interferencePain interference scoresPain intensity scoresGroup C patientsA Decision Support Tool for Allogeneic Hematopoietic Stem Cell Transplantation for Children With Sickle Cell Disease: Acceptability and Usability Study
Veludhandi A, Ross D, Sinha C, McCracken C, Bakshi N, Krishnamurti L. A Decision Support Tool for Allogeneic Hematopoietic Stem Cell Transplantation for Children With Sickle Cell Disease: Acceptability and Usability Study. JMIR Formative Research 2021, 5: e30093. PMID: 34709190, PMCID: PMC8587189, DOI: 10.2196/30093.Peer-Reviewed Original ResearchHematopoietic stem cell transplantationSickle cell diseaseAllogeneic hematopoietic stem cell transplantationHealth care providersStem cell transplantationCare providersCell transplantationPatient consultsCell diseaseHCT comorbidity indexPhysician-patient collaborationOttawa Decision Support FrameworkChronic blood transfusionsDisease-modifying therapiesTransplant registry dataMost participantsHealth care settingsQuality of lifePatient-specific measuresCurative intentComorbidity indexHCT outcomesBlood transfusionRisk factorsPatient managementAssessing Patient Preferences for Treatment Options for Pediatric Sickle Cell Disease: A Critical Review of Quantitative and Qualitative Studies
Katoch D, Krishnamurti L. Assessing Patient Preferences for Treatment Options for Pediatric Sickle Cell Disease: A Critical Review of Quantitative and Qualitative Studies. Patient Preference And Adherence 2021, 15: 2221-2229. PMID: 34629865, PMCID: PMC8493010, DOI: 10.2147/ppa.s264918.Peer-Reviewed Original ResearchSickle cell diseasePatient preferencesTreatment preferencesCell diseasePediatric sickle cell diseaseHematopoietic cell transplantPatients' treatment preferencesBurden of careQuality of lifeQualitative studyStandard gamble studyCurative intentRed blood cellsSupportive careSubstantial morbidityCell transplantImpaired qualityTreatment optionsIntravascular hemolysisPatient utilitiesPremature mortalityCaregiver perspectivesTreatment alternativesBlood cellsUtility studies
2020
Educational needs of patients and caregivers living with sickle cell disease results in development of web‐based patient decision aid
Ross D, Sinha C, Bakshi N, Krishnamurti L. Educational needs of patients and caregivers living with sickle cell disease results in development of web‐based patient decision aid. Journal Of Advanced Nursing 2020, 77: 1432-1441. PMID: 33277763, DOI: 10.1111/jan.14704.Peer-Reviewed Original ResearchConceptsSickle cell diseasePatients/caregiversWeb-based patient decision aidQuality of lifeTreatment optionsCell diseasePatient decision aidWeb-based decision aidPotential treatment optionHealthcare provider educationInitial needs assessmentDecision aidAdult patientsAvailable therapiesProvider educationSemi-structured qualitative interviewsPatientsHealthcare providersWay patientsDecisional needsInternet-based searchDiseaseCaregiversFurther recruitmentNeeds assessmentShould young children with sickle cell disease and an available human leukocyte antigen identical sibling donor be offered hematopoietic cell transplantation?
Krishnamurti L. Should young children with sickle cell disease and an available human leukocyte antigen identical sibling donor be offered hematopoietic cell transplantation? Hematology/Oncology And Stem Cell Therapy 2020, 13: 53-57. PMID: 32202246, DOI: 10.1016/j.hemonc.2019.12.008.Peer-Reviewed Original ResearchConceptsHematopoietic cell transplantationSickle cell diseaseQuality of lifeOverall survivalCell transplantationCell diseaseYoung childrenHLA-identical siblingsHuman leukocyte antigenSevere clinical presentationAvailable human leukocyte antigenFree survivalOrgan dysfunctionClinical presentationLeukocyte antigenIdentical siblingsPremature mortalityAvailable HLAYounger ageTransplantationHLAAgeDiseaseChildrenSurvival
2018
Pain catastrophizing is associated with poorer health-related quality of life in pediatric patients with sickle cell disease
Bakshi N, Lukombo I, Belfer I, Krishnamurti L. Pain catastrophizing is associated with poorer health-related quality of life in pediatric patients with sickle cell disease. Journal Of Pain Research 2018, 11: 947-953. PMID: 29773954, PMCID: PMC5947835, DOI: 10.2147/jpr.s151198.Peer-Reviewed Original ResearchSickle cell diseasePoor health-related qualityHealth-related qualityHealth care utilizationPoor HRQOLPain intensityCare utilizationCell diseaseDepressive symptomsPrior health care utilizationPsychological factorsPain-related outcomesRace-matched controlsCross-sectional studyQuality of lifePaucity of dataSCD outcomesPain burdenPediatric patientsRed blood cellsPain interferenceMultisystem involvementPain phenotypingHRQoLPsychological covariates
2015
A multicenter randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children
Brousseau D, Scott J, Badaki-Makun O, Darbari D, Chumpitazi C, Airewele G, Ellison A, Smith-Whitley K, Mahajan P, Sarnaik S, Casper T, Cook L, Dean J, Leonard J, Hulbert M, Powell E, Liem R, Hickey R, Krishnamurti L, Hillery C, Nimmer M, Panepinto J, Network F. A multicenter randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children. Blood 2015, 126: 1651-1657. PMID: 26232172, PMCID: PMC4591790, DOI: 10.1182/blood-2015-05-647107.Peer-Reviewed Original ResearchConceptsSickle cell pain crisisLength of stayPediatric Emergency Care Applied Research NetworkPain crisisIntravenous magnesiumOpioid useNormal saline placeboStudy drug infusionPlacebo-controlled trialHealth-related qualityQuality of lifeMorphine equivalentsStudy drugSaline placeboSecondary outcomesStandard therapyHemoglobin SSPediatric patientsPrimary outcomeDrug infusionPain relieversPlaceboStayChildren 4Group demographics
2014
A Multi-Center Randomized Controlled Trial of Intravenous Magnesium for Sickle Cell Pain Crisis in Children
Brousseau D, Scott J, Badaki O, Darbari D, Chumpitazi C, Airewele G, Ellison A, Smith-Whitley K, Mahajan P, Sarnaik S, Casper T, Cook L, Dean M, Leonard J, Hulbert M, Powell E, Liem R, Hickey R, Krishnamurti L, Hillery C, Panepinto J. A Multi-Center Randomized Controlled Trial of Intravenous Magnesium for Sickle Cell Pain Crisis in Children. Blood 2014, 124: 88. DOI: 10.1182/blood.v124.21.88.88.Peer-Reviewed Original ResearchSickle cell pain crisisLength of stayAcute chest syndromePediatric Emergency Care Applied Research NetworkQuality of lifePain crisisPediatric emergency medicine physiciansOpioid useIntravenous magnesiumSickle cell diseaseEmergency medicine physiciansMorphine equivalentsPlacebo groupStudy drugAdverse eventsDrug infusionCell diseaseMedicine physiciansHistory of ACSMAGIC studyMulti-Center Randomized Controlled TrialSickle cell vasoocclusive crisisAcute intervention trialDecreased opioid useFirst drug infusion